Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
boston
6
×
boston blog main
drugs
6
×
life sciences
national blog main
boston top stories
national top stories
clinical trials
fda
crispr
medical devices
new york blog main
new york top stories
people
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
texas
texas blog main
texas top stories
akcea therapeutics
allergan
alnylam pharmaceuticals
antibiotics
arvinas
astrazeneca
australia
barry greene
bill mckeon
bioinnovation capital
biolabs
boston university
boulder/denver
boulder/denver blog main
boulder/denver top stories
cancer
carbapenem-resistant enterobacteriaceae
celgene
What
medical
innovation
life
medicine
ago
allergan
alnylam
announced
approve
awaits
biological
biotech
biotechs
blessing
bosley
center
center’s
ceo
cf
check
chose
clinical
close
company
crisis
crispr
crossed
cusp
cystic
decades
decision
depart
developer
device
director
discovered
driving
drug
editas
editing
Language
unknown
unset
Current search:
drugs
×
boston
×
biotech
×
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
JLabs’ Luby Takes the Reins at TMC Innovation Institute in Houston
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision